secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0001384101-24-000004
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.01, 9.01, 3.02
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte completes $70M acquisition of C2i Genomics; milestone payments up to $25M
--------------------------------------------------------------------------------

- Purchase price of $70M paid to C2i Genomics securityholders, subject to customary adjustments.
- Up to $25M in additional milestone payments payable in cash or stock over next two years.
- Veracyte to issue up to 2,698,349 shares as stock consideration; cash in lieu for non-accredited investors.
- SEC granted partial waiver from certain financial statement requirements under Rule 3-13.
- Closing occurred on February 5, 2024; audited C2i financials to be filed within 71 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410124000004/0001384101-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410124000004/vcyt-20240205.htm
  HTML page:      https://secwatch.observer/filing/0001384101-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer